149 related articles for article (PubMed ID: 11979313)
1. Prophylactic T cell infusion after T cell-depleted bone marrow transplantation in patients with refractory lymphoma.
Lee CK; de Magalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD
Bone Marrow Transplant; 2002 Apr; 29(7):615-20. PubMed ID: 11979313
[TBL] [Abstract][Full Text] [Related]
2. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
Lee CK; deMagalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD
Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494
[TBL] [Abstract][Full Text] [Related]
3. Prophylactic reinfusion of T cells for T cell-depleted allogeneic bone marrow transplantation.
Lee CK; Gingrich RD; deMagalhaes-Silverman M; Hohl RJ; Joyce JK; Scott SD; Wen BC; Schlueter A
Biol Blood Marrow Transplant; 1999; 5(1):15-27. PubMed ID: 10232737
[TBL] [Abstract][Full Text] [Related]
4. Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation.
Godder KT; Henslee-Downey PJ; Mehta J; Park BS; Chiang KY; Abhyankar S; Lamb LS
Bone Marrow Transplant; 2007 Jun; 39(12):751-7. PubMed ID: 17450185
[TBL] [Abstract][Full Text] [Related]
5. T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect.
Barrett AJ; Mavroudis D; Tisdale J; Molldrem J; Clave E; Dunbar C; Cottler-Fox M; Phang S; Carter C; Okunnieff P; Young NS; Read EJ
Bone Marrow Transplant; 1998 Mar; 21(6):543-51. PubMed ID: 9543057
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
[TBL] [Abstract][Full Text] [Related]
7. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
8. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity.
Peggs KS; Mackinnon S; Williams CD; D'Sa S; Thuraisundaram D; Kyriakou C; Morris EC; Hale G; Waldmann H; Linch DC; Goldstone AH; Yong K
Biol Blood Marrow Transplant; 2003 Apr; 9(4):257-65. PubMed ID: 12720218
[TBL] [Abstract][Full Text] [Related]
9. CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens.
Kalaycio M; Rybicki L; Pohlman B; Sobecks R; Ball E; Cook D; Andresen S; Kuczkowski E; Bolwell B
Bone Marrow Transplant; 2005 Feb; 35(3):247-52. PubMed ID: 15580282
[TBL] [Abstract][Full Text] [Related]
10. The impact of partial T cell depletion on overall transplant-related toxicity, graft function and survival after HLA-identical allogeneic bone marrow transplantation in standard risk adult patients with leukemia.
Schots R; Van Riet I; Ben Othman T; Trullemans F; De Waele M; Van Camp B
Bone Marrow Transplant; 2001 Nov; 28(10):917-22. PubMed ID: 11753544
[TBL] [Abstract][Full Text] [Related]
11. T-cell depleted peripheral blood stem cell allotransplantation with T-cell add-back for patients with hematological malignancies: effect of chronic GVHD on outcome.
Montero A; Savani BN; Shenoy A; Read EJ; Carter CS; Leitman SF; Mielke S; Rezvani K; Childs R; Barrett AJ
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1318-25. PubMed ID: 17162214
[TBL] [Abstract][Full Text] [Related]
12. T cell-depleted allogeneic bone marrow transplantation for high-risk non-Hodgkin's lymphoma: clinical and molecular follow-up.
Juckett M; Rowlings P; Hessner M; Keever-Taylor C; Burns W; Camitta B; Casper J; Drobyski WR; Hanson G; Horowitz M; Lawton C; Margolis J; Peitryga D; Vesole D
Bone Marrow Transplant; 1998 May; 21(9):893-9. PubMed ID: 9613781
[TBL] [Abstract][Full Text] [Related]
13. CD6+ T cell-depleted allogeneic bone marrow transplantation for non-Hodgkin's lymphoma.
Soiffer RJ; Freedman AS; Neuberg D; Fisher DC; Alyea EP; Gribben J; Schlossman RL; Bartlett-Pandite L; Kuhlman C; Murray C; Freeman A; Mauch P; Anderson KC; Nadler LM; Ritz J
Bone Marrow Transplant; 1998 Jun; 21(12):1177-81. PubMed ID: 9674848
[TBL] [Abstract][Full Text] [Related]
14. Selected CD34 blood cell allografts for older patients: low transplant-related mortality, graft failure and acute GvHD.
Roberts MM; Dyson P; Rawling C; Thorp D; Rawling T; White D; Horvath N; Bardy P; Hui CH; Dart GW; To LB; Hughes TP
Cytotherapy; 2003; 5(6):534-41. PubMed ID: 14660049
[TBL] [Abstract][Full Text] [Related]
15. Safe and efficacious allogeneic bone marrow transplantation for nonmalignant disorders using partial T cell depletion and no posttransplantation graft-versus-host-disease prophylaxis.
Elhasid R; Arush MB; Zaidman I; Leiba R; Barak AB; Postovsky S; Haddad N; Katz T; Pollack S; Sami I; Gidoni O; Rubin D; Mandel H; Attias D; Reisner Y; Etzioni A; Rowe JM
Biol Blood Marrow Transplant; 2007 Mar; 13(3):329-38. PubMed ID: 17317586
[TBL] [Abstract][Full Text] [Related]
16. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation.
Bacigalupo A; Lamparelli T; Barisione G; Bruzzi P; Guidi S; Alessandrino PE; di Bartolomeo P; Oneto R; Bruno B; Sacchi N; van Lint MT; Bosi A;
Biol Blood Marrow Transplant; 2006 May; 12(5):560-5. PubMed ID: 16635791
[TBL] [Abstract][Full Text] [Related]
17. A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation.
Winston DJ; Antin JH; Wolff SN; Bierer BE; Small T; Miller KB; Linker C; Kaizer H; Lazarus HM; Petersen FB; Cowan MJ; Ho WG; Wingard JR; Schiller GJ; Territo MC; Jiao J; Petrarca MA; Tonetta SA
Bone Marrow Transplant; 2001 Jul; 28(2):187-96. PubMed ID: 11509937
[TBL] [Abstract][Full Text] [Related]
18. Prevention of graft-versus-host disease with T cell depletion or cyclosporin and methotrexate. A randomized trial in adult leukemic marrow recipients.
Ringdén O; Pihlstedt P; Markling L; Aschan J; Båryd I; Ljungman P; Lönnqvist B; Tollemar J; Janossy G; Sundberg B
Bone Marrow Transplant; 1991 Mar; 7(3):221-6. PubMed ID: 2059758
[TBL] [Abstract][Full Text] [Related]
19. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol.
Alvarez I; Sureda A; Caballero MD; Urbano-Ispizua A; Ribera JM; Canales M; García-Conde J; Sanz G; Arranz R; Bernal MT; de la Serna J; Díez JL; Moraleda JM; Rubió-Félix D; Xicoy B; Martínez C; Mateos MV; Sierra J
Biol Blood Marrow Transplant; 2006 Feb; 12(2):172-83. PubMed ID: 16443515
[TBL] [Abstract][Full Text] [Related]
20. [Influence of graft-versus-host disease on long-term survival of 26 patients with hematologic malignancies after transplantation].
Lin Q; Dong M; Wang QM; Wen JY; Wu XY
Ai Zheng; 2006 Oct; 25(10):1261-5. PubMed ID: 17059772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
